Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Net Income (2023 - 2025)

Historic Net Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Net Income rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Net Income is -$35.3 million, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Net Income ranged from a high of $1.9 billion in Q2 2024 and a low of -$92.0 million during Q4 2023
  • In the last 3 years, Inhibrx Biosciences' Net Income had a median value of -$45.5 million in 2023 and averaged $139.0 million.
  • In the last 5 years, Inhibrx Biosciences' Net Income soared by 404884.6% in 2024 and then tumbled by 10154.22% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Net Income stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then increased by 26.34% to -$35.3 million in 2025.
  • Its Net Income stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.